As promised, we at Undiscovered Equities would like to take this opportunity to showcase our top 10 investment opportunities for 2010.
Last year we urged our subscribers to ignore the nervousness of the times and take advantage of the opportunity that the period of forced liquidation created. As our results show, it proved to be, as Warren Buffett said, “one of the greatest buying opportunities of our lifetime.”
Our advice to our subscribers this year is to remain patient, have a long term outlook and continue to invest in great businesses: ones that can make huge profits and grow dramatically even in today’s economic environment.
Looking ahead we expect that the market for crude oil will continue to grow, especially as certain areas of the world such as India and China continue to modernize. We feel that oil prices will trade in a range between $66 and $90 per barrel.
This year however we are avoiding domestic natural gas exploration plays as we believe gas prices will remain under pressure due to the recent robust shale finds and the challenging US economic environment. In the past we have focused primarily on the energy sector, but this year we have chosen to diversify as several extraordinary opportunities have captured our attention.
We expect these 10 stocks to outperform in the New Year and as always it is important to keep some cash in reserves for extraordinary opportunities.
All of us at Undiscovered Equities hope you had a great holiday season and we wish you success and prosperity in the New Year!
Endeavour Financial (TSX: EDV) $1.77
Ironically, we were introduced to Endeavour through their interest in Manas Petroleum’s giant concessions in Albania. TSX Listed Endeavour Financial is an independent merchant banking company focused on the global natural resources sector. Endeavour offers advisory services in project, corporate and debt capital markets; equity financings; mergers and acquisitions; and strategic business development. Endeavour also has a gold-focused investment strategy and seeks maximum returns by identifying, investing in and consolidating junior gold mining companies as well as some oil and gas companies. Many resource investors know the Vancouver based financier Frank Giustra. Endeavour is Giustra’s most public investment vehicle and together they have been behind some of the biggest wins in the resource market this decade, including Wheaton River Gold, Northern Orion Resources and Urasia Energy. Endeavour’s track record has been impeccable, and we think they will continue to produce significant returns for their shareholders for years to come. We also feel that the continued weakness in the dollar will add to Endeavour’s success.
Far East Energy Corporation (OTC BB: FEEC) $0.46
Houston, Texas based Far East Energy Corporation together with its subsidiaries, focuses on the exploration, development, production, and sale of coalbed methane gas (CBM) in the People's Republic of China. The company owns interests in three production sharing contracts, which cover the 485,000-acre Shouyang Block in Shanxi Province; the 573,000-acre Qinnan Block in Shanxi Province; and the Enhong and Laochang areas, which total 265,000 acres, in Yunnan Province. Far East Energy has formed an alliance related to its Qinnan Block with Arrow Energy International Pte Ltd (Arrow), the Singapore-based subsidiary of Arrow Energy Limited, a large Australian CBM producer. In addition Far East recently announced that gas production from the Shouyang Block in the Shouyang Block of Shanxi Province, China, has begun and is accelerating rapidly. The Shanxi project in full development has the potential to become one of the largest CBM projects in the world. In a country that desperately needs clean energy sources, Far East Energy has the potential to produce between 10 and 20 TFC of natural gas. It is also important to note that the price of natural gas in China has gone up over the last 3 years as opposed to the US where prices have plummeted. We have been following Far East for quite some time and now more than ever we are aggressive buyers.
Gran Tierra Energy Inc. (NYSE Amex: GTE, TSX: GTE) $5.74
Gran Tierra Energy, Inc. is an international oil and gas exploration and production company operating in South America. The Company currently holds interests in producing and prospective properties in Colombia, Argentina and Peru. The Company strategy is focused on establishing a portfolio of drilling opportunities to exploit undeveloped reserves to grow production, as well as undertaking exploration drilling to grow future reserves. Current production from operations exceeds 13,000 BOPD net after royalty. The Company recently announced a capital spending program of $195 million in 2010 for exploration and production that includes the drilling of seven exploration wells in Colombia, four exploration wells in Peru and re-entry and side-tracking of a well in Argentina. The approved 2010 budget also includes funds for 2-D and 3-D seismic acquisition programs in Colombia, Peru, and Argentina and facility upgrades in Colombia and Argentina. Gran Tierra Energy had $151.6 million in cash at the end of Q3 2009 and has no debt. The 2010 work program and budget is expected to be funded from cash-flow from operations with the balance from cash on hand. This is a very strong well run company and we feel they will continue to drill economic wells as they enter next year with the largest exploration drilling program in the company's history.
Houston American Energy Corp. (Nasdaq: HUSA) $6.13
Houston American Energy Corp. is an oil and gas exploration and production company whose activities are focused on several concessions in the South American country of Colombia. Houston American continues to generate strong operating cash flow from their production base in Colombia with their interest in the Hupecol project which is currently producing over 850 net barrels of oil per day and growing. In 2009, Houston American recently added 2 extremely valuable assets to their portfolio of properties. The Company partnered up with SK Energy Co. LTD to develop the highly prolific CPO 4 Block covering 345,452 acres which is situated along the productive western margin of the Llanos Basin in Colombia. Houston American now controls 25% of the CPO 4 Block which encompasses the same structure as the Corcel block where well rates of between 2,000 and 10,000 barrels of oil per day have recently been announced. SK Energy believes the CPO 4 Block has over 100 viable drilling locations with estimated recoverable reserves of 1-4 billion barrels. A 3-D seismic program is ongoing. In 2009 Houston American also inked a substantial farmout agreement with Shona Energy (Colombia) LTD. to earn a 12.5% interest in the Serrania Block, which is adjacent to the recent Ombu discovery which contains an estimated 1 billion barrels of oil in place. With the largest exploration budget in its history approved and funded Houston American enters 2010 with considerable momentum and we feel the stock will break out to new levels.
Hyperdynamics Corporation (NYSE Amex: HDY) $0.88
Sugar Land, Texas based Hyperdynamics Corporation engages in the exploration and production of oil and gas in West Africa. It holds certain contract rights for the exploration and exploitation of oil and gas in an approximately 80,000 square kilometer concession off the coast of the Republic of Guinea. The last several months have been very exciting for Hyperdynamics as they have partnered up with 2 very strong and capable companies. First Hyperdynamics signed a binding sale and purchase agreement (S&PA) with Aberdeen, Scotland, based Dana Petroleum PLC under which Dana has agreed to acquire a 23 percent participating interest in Hyperdynamics' oil and gas concession offshore the Republic of Guinea for $19.6 million. In addition Hyperdynamics has signed an agreement for exclusive dealing and letter of intent (the "LOI") with Spain's largest oil company Repsol YPF, S.A. (BMAD: REP and NYSE: REP) under which the two companies will negotiate the assignment to Repsol a 37 percent interest in Hyperdynamics' oil and gas concession offshore the Republic of Guinea for $31.5 million. Repsol also would be the operator of the Guinea project. Ray Leonard, Hyperdynamics President and Chief Executive Officer, said, "Dana Petroleum and Repsol bring significant experience to jointly explore our concession in Northwest Africa, as Repsol and Dana have successfully partnered in the past on exploration projects in Northwest Africa. "Assuming we reach definitive agreements with Repsol, Hyperdynamics will retain a 40 percent working interest in the Guinea concession and will be in a stronger financial position, with more than $51 million upon the entry into full legal effect of the production sharing contract clarification to fund our share of 3D seismic and drilling required during the exploratory period. We look forward to working with both companies to explore and develop this large, highly prospective offshore tract." If successful, we feel this company has potential to grow into a multibillion dollar company.
ICOP Digital, Inc. (Nasdaq: ICOP) $0.44ICOP Digital, Inc. is a leading provider of mobile video solutions for Law Enforcement, Fire, EMS, Military, and Transportation markets, worldwide. ICOP solutions help the public and private sectors improve security, reduce losses, and mitigate risks through the capture, live streaming and secure management of high quality video and audio. ICOP has already penetrated law enforcement markets in 49 states, as well as key international markets, including Mexico and Saudi Arabia. ICOP Digital is currently the only approved vendor of in-car video equipment for the Kingdom of Saudi Arabia, contracted through their Ministry of Interior. We estimate the market in Saudi Arabia to be over 100,000 security vehicles and feel ICOP has great potential to capture this and other key markets in the Middle East. A few domestic clients include Alaska State Troopers, Wyoming State Troopers, Mobile Police Department in Alabama, and Hartford Police Department in Connecticut. ICOP's products have proven to be of the utmost caliber of quality in the industry, as Raytheon recently signed a 5 year agreement to sell ICOP products worldwide. We believe this to be a game changing event for the company and partnering up with Raytheon will open up significant markets to ICOP's array of products. Globally, security continues to be a major concern, and video is proving to be a key component in the growth of the security industry. We believe significant monies will be spent to modernize current systems, worldwide. Therefore, we believe 2010 will be a breakout year for ICOP.
InterOil Corporation (NYSE: IOC) $77.07
InterOil Corporation is developing a vertically integrated energy business whose primary focus is Papua New Guinea and the surrounding region. InterOil's assets consist of petroleum licenses covering about 4 million acres, an oil refinery, and retail and commercial distribution facilities, all located in Papua New Guinea. In addition, InterOil is a shareholder in a joint venture established to construct an LNG plant on a site adjacent to InterOil's refinery in Port Moresby. Congratulations to all longs as 2009 has been a truly spectacular year for the company. With 2 world record breaking wells in Antelope we wonder what Phil will do for an encore in 2010. Although the stock price has moved significantly higher we still feel there are many short and long term catalysts that will propel InterOil to new levels. Some near term examples of the upside here are possible deals announced per China, India, Japan, etc., a possible oil find announcement, further news on the proposed condensate plant, and more analyst coverage.
Manas Petroleum (OTC BB: MNAP) $0.55
Manas Petroleum is an international oil and gas company with primary focus on exploration and development in south-eastern Europe, Central Asia and South America. Since inception, Manas has acquired a spectacular portfolio of high impact exploration properties. In keeping with their philosophy of building a strong and enduring resource base, earlier in 2009 Manas added blocks 2 and 3 in Albania, blocks 13 and 14 in Mongolia and the Western blocks in Tajikistan, expanding their portfolio from 11 to 16 blocks in 5 countries; we now believe that Manas controls in excess of 4 Billion Barrels of Recoverable Oil. Every one of the Company’s giant projects are moving forward and maturing toward production. In Albania, Manas now controls six giant exploration blocks near Europe's largest onshore production. Independent reports from Gustavson (2008) assign (P50) of 3 billion barrels in block A, B, D and E (12.3 billion barrels of oil in place). Two of Manas' original four blocks are now drill-ready. In 2009 the council of ministers ratified the production-sharing contract on the two former Oxy blocks to DWM Petroleum, a subsidiary of Manas. These blocks are within the area where most of Bankers Petroleum's current shallow oil production derives from. Manas has the rights to explore the deeper targets in block two where Bankers is producing oil, and where in 2001 Occidental made a light oil discovery. In November Manas entered into a letter of intent to spin off a portion of its interest in its Albanian project to a TSX-V listed company WWI Resources ("WWI") which is controlled by one of the largest and most successful North American resource investors, Frank Giustra. We believe this is an excellent transaction for Manas as it will create significant shareholder value moving forward. The closing is expected to be completed during the first several weeks of the New Year. In Kyrgyzstan, Manas has signed a $54 million USD farm-out agreement with Santos LTD ADR, covering 1.2 billion barrels in place (Scott Pickford, 2005). Santos will continue to drill with Manas on their 6 shallow and deep well program in 2010. Manas' Development of its license in Tajikistan is now covered by an option farm-in agreement with Santos, where a seismic program is moving forward. In Mongolia Manas will expand their exploration with a seismic campaign to encompass approximately 20, 000 square kilometers. Additionally, to expose Manas to a much larger and more sophisticated audience, the Company is continuing to take the necessary steps to become listed on the TSX Venture stock exchange. Importantly, next year looks set to see a very significant acceleration of Manas Petroleum’s activities and surely this company has the greatest upside potential on our list.
Nutra Pharma Corporation (OTC BB: NPHC) $0.35
Nutra Pharma Corporation was founded in 2000 and is based in Plantation, Florida. The company, through its subsidiaries, operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, pain, autoimmune, and infectious diseases. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company recently launched an Over-The-Counter (OTC) Treatment for Stage 2 (Moderate to Severe) Chronic Pain called Cobroxin. Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain and is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain. Nutra Pharma also has formulated a higher dose pharmaceutical grade treatment for stage 3 (severe) pain called Nyloxin. Nyloxin Oral Spray is an oral formulation of diluted cobra venom prepared according to the requirements of the Homeopathic Pharmacopoeia of the United States (HPUS) and its supporting texts. What really drew me to this company is the exceptional management team lead by CEO Rik J Deitsch. With sales of Cobroxin ramping up, Nutra Pharma appears to be well on the way to becoming a major success.
Xiom (OTC BB: XMCP) $0.26Environmental Infrastructure Holdings (EIHC) is the parent company of various environmental manufacturing, engineering, and services companies. Currently, EIHC has two subsidiaries Equisol, LLC and Xiom Corp. as well as investments into various joint ventures and partnerships. Recognized in 2008 by INC Magazine as the 7th fastest growing private Environmental Services Company in America, Equisol, LLC, is a unique equipment solutions provider specializing in the water and wastewater industry. Their team of top rated engineers specializes in automation equipment and services across multiple industries where water use and automation are important. From consulting and design of equipment systems, to sales, installation and maintenance services, Equisol can address their customer's needs in many diverse applications. Equisol provides cost effective equipment strategies to allow users of water and producers of wastewater to achieve profitability while focusing on their core business activities. Through Equisol's association with world technology leaders, they are able to supply a broad spectrum of high quality products. Their staff, with over 300 years of engineering experience in equipment automation, uses these technologies to select the most effective solution for their customer's applications. Other recognition that Equisol has achieved include the Entrepreneur Hot 100 Fastest New Companies in 2004, INC5000 ranking of #621 for 2007, and 2009 Philadelphia 100 recognizing the fastest growing private companies in the region. Xiom Corp. is a technology business offering delivery of plastic powder coatings at on-site locations utilizing the XIOM 1000 System. Powder coating currently is a process in which metal parts are brought into a factory environment where they are cleaned and prepared to receive a powder coating. Plastic in powder form is then applied to the various metal parts by means of an electrostatic charge that causes the powder to adhere to the surface. The coated part is then heated in an oven for a period of time to cause the plastic to melt and adhere to the substrate. Although they use plastic powder, they do not electro-statically charge that powder in order for it to adhere to a substrate. Xiom uses a different mechanism which simultaneously applies and fuses the powder to a substrate. The advantage of this process is that the coating process is totally portable and can be applied anywhere, not necessarily in a factory setting, and can be applied without use of an oven to cure the coating, and can be applied to most substrates in addition to the metal substrate to which powder coatings are traditionally applied in a factory, using an oven. The CEO of the combined entities, Mr. Michael Parrish has extensive operational and general management experience; his focus is on financial performance and strategic alliances. Prior to running Equisol, Mr. Parrish held various executive positions in several General Electric Companies where he served in positions such as General Manager for global logistics and services for GE’s Water business, and, earlier, as Managing Director for GE Capital specializing in ecommerce, six sigma, and productivity of several of GE’s equipment management groups. Prior to GE, Mr. Parrish served for 14 years active duty in the U.S. Army where he held various leadership positions of increasing responsibility as an Army Aviator culminating as a member of the Army Acquisition Corps. Mr. Parrish has a Bachelor’s degree in Engineering from the U.S. Military Academy at West Point as well as a Masters degree in Astronautically Engineering from Stanford University and an MBA with honors from the Wharton School at the University of Pennsylvania. He is the current President of the West Point Society of Philadelphia and serves on the boards of the USO of SE PA/NJ and the Delaware Valley Industrial Resources Council. We think this company is extremely undervalued given the fact that the applications for Xiom's products are virtually endless. With the addition of Mike Parish and the Equisol team we believe revenues will grow dramatically in 2010.
Thursday, December 31, 2009
Tuesday, December 29, 2009
Undiscovered Equities Top 10 up 168%
Undiscovered Equities Top 10 Picks for 2009 Update
Company
Ultra Petroleum (UPL)
Reference Price $34.03
Recent Price $52.64
Total Return 55%
Company
Manas Petroleum (MNAP)
Reference Price $0.25
Recent Price $0.55
Total Return 120%
Company
Gran Tierra Energy, Inc. (GTE)
Reference Price $2.56
Recent Price $5.94
Total Return 132%
Company
InterOil (IOC)
Reference Price $11.75
Recent Price $77.29
Total Return 558%
Company
Southwestern Energy (SWN)
Reference Price $29.97
Recent Price $49.99
Total Return 69%
Company
American Oil & Gas, Inc. (AEZ)
Reference Price $0.71
Recent Price $4.28
Total Return 503%
Company
Anadarko Petroleum Corporation (APC)
Reference Price $37.95
Recent Price $64.20
Total Return 70%
Company
BPZ Resources, Inc (BPZ)
Reference Price $6.17
Recent Price $9.51
Total Return 54%
Company
Marathon Oil (MRO)
Reference Price $26.65
Recent Price $31.53
Total Return 21.50%
Company
Houston American Energy Corp. (HUSA)
Reference Price $2.97
Recent Price $5.96
Total Return 101%
* Total return includes dividends
Undiscovered Equities Top 10 2009 Average Return 168%
Undiscovered Equities is currently offering a trial subscription.
For more information please call 1-800-404-8982 or visit our website at http://www.undiscoveredequities.com
Sincerely,
Kevin McKnight
1-800-404-8982
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
Company
Ultra Petroleum (UPL)
Reference Price $34.03
Recent Price $52.64
Total Return 55%
Company
Manas Petroleum (MNAP)
Reference Price $0.25
Recent Price $0.55
Total Return 120%
Company
Gran Tierra Energy, Inc. (GTE)
Reference Price $2.56
Recent Price $5.94
Total Return 132%
Company
InterOil (IOC)
Reference Price $11.75
Recent Price $77.29
Total Return 558%
Company
Southwestern Energy (SWN)
Reference Price $29.97
Recent Price $49.99
Total Return 69%
Company
American Oil & Gas, Inc. (AEZ)
Reference Price $0.71
Recent Price $4.28
Total Return 503%
Company
Anadarko Petroleum Corporation (APC)
Reference Price $37.95
Recent Price $64.20
Total Return 70%
Company
BPZ Resources, Inc (BPZ)
Reference Price $6.17
Recent Price $9.51
Total Return 54%
Company
Marathon Oil (MRO)
Reference Price $26.65
Recent Price $31.53
Total Return 21.50%
Company
Houston American Energy Corp. (HUSA)
Reference Price $2.97
Recent Price $5.96
Total Return 101%
* Total return includes dividends
Undiscovered Equities Top 10 2009 Average Return 168%
Undiscovered Equities is currently offering a trial subscription.
For more information please call 1-800-404-8982 or visit our website at http://www.undiscoveredequities.com
Sincerely,
Kevin McKnight
1-800-404-8982
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
Manas Is A Step Closer To Completing Albanian Transaction (OTCBB:MNAP)
BAAR, SWITZERLAND -- 12/29/09 -- Manas Petroleum Corporation ("Manas") (OTCBB: MNAP) is pleased to report that the financing arrangement and the due diligence between Manas and WWI resources for the Albanian project are proceeding as planned and are on-track to maximize shareholder value.
Manas is currently progressing on administrative, legal and compliance issues, as required before closing. The closing is expected to be completed during the first several weeks of the New Year.
About Manas Petroleum: Manas Petroleum is an international oil and gas company, focusing on activities in South-Eastern Europe, Central Asia and South America. Details of these projects are located on the Company's website: www.manaspete.com
Undiscovered Equities is currently offering a trial subscription. For more information please call 1-800-404-8982 or visit our website at http://www.undiscoveredequities.com
Sincerely,
Kevin McKnight
1-800-404-8982
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
Wednesday, December 16, 2009
Environmental Infrastructure Holdings Announces Board Realignment and Establishes Plan for Growth (OTCBB:XMCP)
Environmental Infrastructure Holdings Announces Board Realignment and Establishes Plan for Growth (OTCBB:XMCP)
12/16/09
Michael D. Parrish, Chairman of Environmental Infrastructure Holdings, restructured and expanded the board of directors as a result of the merger completed on 7 December 2009. The following actions were taken:
1. Andrew B. Mazzone resigned as President and CEO of each of the Company and XIOM. Mr. Mazzone will continue to serve as a member of the Board of Directors of each of the Company and XIOM.
2. Additionally, Thomas Gardega resigned as a director and as Secretary of each of the Company and XIOM.
3. Effective as of December 7, 2009, the following individuals were elected to the Board of
Directors of the Company:
Name Position
Michael D. Parrish Chairman of the Board of Directors/CEO, President
Gregory N. Moore Director and Chairman of the Audit Committee
Kurt M. Given Treasurer/Director
James W. Zimbler Secretary/Director
Andrew B. Mazzone Director
About the Board:
Michael D. Parrish, Chairman, CEO & President - Mr. Parrish has extensive operational and general management experience; his focus is on financial performance and strategic alliances. Mr. Parrish has over 24 years of leadership and finance experience in a variety of global firms. Prior to Equisol, Mr. Parrish held various executive positions in several General Electric Companies where he served in positions such as General Manager for global logistics and services for GE's Water business, and, earlier, as Managing Director for GE Capital specializing in ecommerce, six sigma, and productivity of several of GE's equipment management groups. Prior to GE, Mr. Parrish served for 14 years active duty in the U.S. Army where he held various leadership positions of increasing responsibility as an Army Aviator culminating as a member of the Army Acquisition Corps. Mr. Parrish has a Bachelor's degree in Engineering from the U.S. Military Academy at West Point as well as a Masters Degree in Astronautical Engineering from Stanford University and an MBA with honors from the Wharton School at the University of Pennsylvania. He is the current President of the West Point Society of Philadelphia and serves on the boards of the USO of SE PA/NJ and the Delaware Valley Industrial Resources Council.
Gregory N. Moore - Mr. Moore has over 25 years of senior management experience in major multi-national companies and extensive international experience in major worldwide markets. He served as the Senior Vice President and Controller of YUM! Brands, Inc. from 2003 to 2005. Prior thereto, Mr. Moore was the Vice President and General Auditor of Yum from 1997 to 2003. Before that, he was with PepsiCo, Inc. and held the position of Vice President and Controller of Taco Bell and Controller of PepsiCo Wines and Spirits International. Since retiring, he has been a frequent speaker and lecturer and currently sits on two boards: Texas Roadhouse, Inc. (NASDAQ) serving as Chairman of the Audit Committee and Nominating & Corporate Governance Committee, and as a member of the Compensation Committee; and 3 Day Blinds, a privately held company owned by two private equity firms, for which he chairs the Audit Committee.
Kurt M. Given - Mr. Given is President & Chief Executive Officer of Equisol and is responsible for the day-to-day business functions and operations of Equisol, including marketing, technology, and linking together sales, administration, and customer relationships. With 20 years of water treatment experience at GE Betz, he has held positions in engineering and management for both the chemical and feed equipment product lines. From 1999 to 2002, he was group Leader and Product Manager for the Equipment team, overseeing all activities including pricing, marketing, profitability, capital equipment, contracts and product management. He has a bachelor of Science degree in Chemical Engineering from Pennsylvania State University and holds a patent for dust control foam generation.
James W. Zimbler - Mr. Zimbler, has been a principal of Keystone Capital Resources, LLC, since its inception in March 2004. Keystone is involved as a consultant in the mergers and acquisitions of public companies and consulting for private companies that wish to access the public markets. Prior to becoming a founding member of Keystone, he was involved in consulting for capital raising, re-capitalization and mergers and acquisitions for various clients. Mr. Zimbler was one of the initial shareholders in Accountabilities, Inc., f/k/a Human Trans Services Holding Corp ("ACBT"). Mr. Zimbler has recently focused his energies in the field of turnarounds of small emerging private and public companies. He has served on the Board of Directors and/or Officer of several companies since 2000.
Andrew B. Mazzone - Mr. Mazzone was Chairman and President of Xiom Corp since its inception in 1998 until December 7, 2009, when he stepped down as Chairman and President and assumed the position of Director. Mr. Mazzone was the President of TTI at the time of the spin-out. He resigned as Sole Officer and Director of TTI on November 1, 2001. Thereafter, TTI acquired and changed its name to Steam Clean USA, Inc. on or about August 15, 2002. On July 1, 2003, Steam Clean USA, Inc. acquired Humana Trans Services Group, Ltd. At this point Mr. Mazzone was invited to become Chairman of the Board of Directors. He served in that position until January 2004, when he resigned as Chairman but remained as a Director and until May 5, 2004, when he resigned from the Board entirely. From 1970 until February 15, 1995, Mr. Mazzone was employed by Metco, Westbury, NY, a subsidiary of the Perkin Elmer Corp., a holding company, which subsidiary, Metco, was engaged in the business of development of metal spraying and metal powders. Mr. Mazzone, as President, resigned from Sulzer Metco after the acquisition of the Company in 1995. From 1995 to October, 2001 Mr. Mazzone was President of Thermaltec International. At Metco, Mr. Mazzone held various positions, including as Director of Logistics, Director of Sales and Marketing, Director of Manufacturing, Executive Vice President and President. Mr. Mazzone has degrees from Babson College, Babson Park, Massachusetts, in finance and an advanced degree in economics, with a specialty in economic history.
With respect to the future plans of the Company, Mr. Parrish, laid out his expectations and vision for the next 12 months and beyond as follows:
1. Target revenue growth rate for the next twelve months of 50% or better is to be achieved through increased organic sales with current customers as well as potential acquisitions. As reference, the combined team's unaudited sales YTD for 2009 are $6.9MM through November.
2. Discussions with several candidates to provide the Company with expanded offerings as well as increased geographic presence in North America.
3. Potentially to increase our position in Extreme Mobile Coatings Worldwide Corp. (OTCBB: "EMWW").
4. Expecting our R&D and manufacturing processes to become ISO certified.
5. Establishment of a responsive customer service organization with training and service centers located in strategic areas throughout the country.
6. Moving aggressively to expand our product offerings and develop a robust pipeline of new products applicable to focused industries, specifically the oil & gas, manufacturing, marine, food & beverage, and commercial markets which includes hospitals, schools, government facilities, etc.
Regarding the merger and integration, Mr. Parrish stated "I am very pleased by the quality, competence, and enthusiasm of the employees of both organizations. As in any integration effort, we will promote the best and brightest while consolidating and minimizing the redundant pieces within the next 90 days to control costs. Equisol brings needed sales, services, and geographic presence to the combined team while Xiom provides the intellectual property, dedicated products, and engineering strength to create a truly consolidated company with reduced dependency upon outside resources. The combination of these two entities establishes a very synergistic environmental services platform focused on our global infrastructure from which we will grow exponentially for many years to come."
About Environmental Infrastructure Holdings Corp.
Environmental Infrastructure Holdings (EIHC) is the parent company of various environmental manufacturing, engineering, and services companies. Currently, EIHC has two subsidiaries Equisol, LLC and Xiom Corp. as well as investments into various joint ventures and partnerships.
Recognized in 2008 by INC Magazine as the 7th fastest growing private Environmental Services Company in America, Equisol, LLC, is a unique equipment solutions provider specializing in the water and wastewater industry. Our team of top rated engineers specializes in automation equipment and services across multiple industries where water use and automation are important. From consulting and design of equipment systems, to sales, installation and maintenance services, Equisol can address our customer's needs in many diverse applications. Equisol provides cost effective equipment strategies to allow users of water and producers of wastewater to achieve profitability while focusing on their core business activities. Through our association with world technology leaders, we are able to supply a broad spectrum of high quality products. Our staff, with over 300 years of engineering experience in equipment automation, uses these technologies to select the most effective solution for our customer's applications. Other recognition that Equisol has achieved include the Entrepreneur Hot 100 Fastest New Companies in 2004, INC5000 ranking of #621 for 2007, and 2009 Philadelphia 100 recognizing the fastest growing private companies in the region.
Xiom Corp. is a technology business offering delivery of plastic powder coatings at on-site locations utilizing the XIOM 1000 System. Powder coating currently is a process in which metal parts are brought into a factory environment where they are cleaned and prepared to receive a powder coating. Plastic in powder form is then applied to the various metal parts by means of an electrostatic charge that causes the powder to adhere to the surface. The coated part is then heated in an oven for a period of time to cause the plastic to melt and adhere to the substrate. Although we use plastic powder, we do not electro-statically charge that powder in order for it to adhere to a substrate. We use a different mechanism which simultaneously applies and fuses the powder to a substrate. The advantage of this process is that the coating process is totally portable and can be applied anywhere, not necessarily in a factory setting, and can be applied without use of an oven to cure the coating, and can be applied to most substrates in addition to the metal substrate to which powder coatings are traditionally applied in a factory, using an oven.
disclaimer: www.undiscoveredequities.com/disclaimer_x.html
12/16/09
Michael D. Parrish, Chairman of Environmental Infrastructure Holdings, restructured and expanded the board of directors as a result of the merger completed on 7 December 2009. The following actions were taken:
1. Andrew B. Mazzone resigned as President and CEO of each of the Company and XIOM. Mr. Mazzone will continue to serve as a member of the Board of Directors of each of the Company and XIOM.
2. Additionally, Thomas Gardega resigned as a director and as Secretary of each of the Company and XIOM.
3. Effective as of December 7, 2009, the following individuals were elected to the Board of
Directors of the Company:
Name Position
Michael D. Parrish Chairman of the Board of Directors/CEO, President
Gregory N. Moore Director and Chairman of the Audit Committee
Kurt M. Given Treasurer/Director
James W. Zimbler Secretary/Director
Andrew B. Mazzone Director
About the Board:
Michael D. Parrish, Chairman, CEO & President - Mr. Parrish has extensive operational and general management experience; his focus is on financial performance and strategic alliances. Mr. Parrish has over 24 years of leadership and finance experience in a variety of global firms. Prior to Equisol, Mr. Parrish held various executive positions in several General Electric Companies where he served in positions such as General Manager for global logistics and services for GE's Water business, and, earlier, as Managing Director for GE Capital specializing in ecommerce, six sigma, and productivity of several of GE's equipment management groups. Prior to GE, Mr. Parrish served for 14 years active duty in the U.S. Army where he held various leadership positions of increasing responsibility as an Army Aviator culminating as a member of the Army Acquisition Corps. Mr. Parrish has a Bachelor's degree in Engineering from the U.S. Military Academy at West Point as well as a Masters Degree in Astronautical Engineering from Stanford University and an MBA with honors from the Wharton School at the University of Pennsylvania. He is the current President of the West Point Society of Philadelphia and serves on the boards of the USO of SE PA/NJ and the Delaware Valley Industrial Resources Council.
Gregory N. Moore - Mr. Moore has over 25 years of senior management experience in major multi-national companies and extensive international experience in major worldwide markets. He served as the Senior Vice President and Controller of YUM! Brands, Inc. from 2003 to 2005. Prior thereto, Mr. Moore was the Vice President and General Auditor of Yum from 1997 to 2003. Before that, he was with PepsiCo, Inc. and held the position of Vice President and Controller of Taco Bell and Controller of PepsiCo Wines and Spirits International. Since retiring, he has been a frequent speaker and lecturer and currently sits on two boards: Texas Roadhouse, Inc. (NASDAQ) serving as Chairman of the Audit Committee and Nominating & Corporate Governance Committee, and as a member of the Compensation Committee; and 3 Day Blinds, a privately held company owned by two private equity firms, for which he chairs the Audit Committee.
Kurt M. Given - Mr. Given is President & Chief Executive Officer of Equisol and is responsible for the day-to-day business functions and operations of Equisol, including marketing, technology, and linking together sales, administration, and customer relationships. With 20 years of water treatment experience at GE Betz, he has held positions in engineering and management for both the chemical and feed equipment product lines. From 1999 to 2002, he was group Leader and Product Manager for the Equipment team, overseeing all activities including pricing, marketing, profitability, capital equipment, contracts and product management. He has a bachelor of Science degree in Chemical Engineering from Pennsylvania State University and holds a patent for dust control foam generation.
James W. Zimbler - Mr. Zimbler, has been a principal of Keystone Capital Resources, LLC, since its inception in March 2004. Keystone is involved as a consultant in the mergers and acquisitions of public companies and consulting for private companies that wish to access the public markets. Prior to becoming a founding member of Keystone, he was involved in consulting for capital raising, re-capitalization and mergers and acquisitions for various clients. Mr. Zimbler was one of the initial shareholders in Accountabilities, Inc., f/k/a Human Trans Services Holding Corp ("ACBT"). Mr. Zimbler has recently focused his energies in the field of turnarounds of small emerging private and public companies. He has served on the Board of Directors and/or Officer of several companies since 2000.
Andrew B. Mazzone - Mr. Mazzone was Chairman and President of Xiom Corp since its inception in 1998 until December 7, 2009, when he stepped down as Chairman and President and assumed the position of Director. Mr. Mazzone was the President of TTI at the time of the spin-out. He resigned as Sole Officer and Director of TTI on November 1, 2001. Thereafter, TTI acquired and changed its name to Steam Clean USA, Inc. on or about August 15, 2002. On July 1, 2003, Steam Clean USA, Inc. acquired Humana Trans Services Group, Ltd. At this point Mr. Mazzone was invited to become Chairman of the Board of Directors. He served in that position until January 2004, when he resigned as Chairman but remained as a Director and until May 5, 2004, when he resigned from the Board entirely. From 1970 until February 15, 1995, Mr. Mazzone was employed by Metco, Westbury, NY, a subsidiary of the Perkin Elmer Corp., a holding company, which subsidiary, Metco, was engaged in the business of development of metal spraying and metal powders. Mr. Mazzone, as President, resigned from Sulzer Metco after the acquisition of the Company in 1995. From 1995 to October, 2001 Mr. Mazzone was President of Thermaltec International. At Metco, Mr. Mazzone held various positions, including as Director of Logistics, Director of Sales and Marketing, Director of Manufacturing, Executive Vice President and President. Mr. Mazzone has degrees from Babson College, Babson Park, Massachusetts, in finance and an advanced degree in economics, with a specialty in economic history.
With respect to the future plans of the Company, Mr. Parrish, laid out his expectations and vision for the next 12 months and beyond as follows:
1. Target revenue growth rate for the next twelve months of 50% or better is to be achieved through increased organic sales with current customers as well as potential acquisitions. As reference, the combined team's unaudited sales YTD for 2009 are $6.9MM through November.
2. Discussions with several candidates to provide the Company with expanded offerings as well as increased geographic presence in North America.
3. Potentially to increase our position in Extreme Mobile Coatings Worldwide Corp. (OTCBB: "EMWW").
4. Expecting our R&D and manufacturing processes to become ISO certified.
5. Establishment of a responsive customer service organization with training and service centers located in strategic areas throughout the country.
6. Moving aggressively to expand our product offerings and develop a robust pipeline of new products applicable to focused industries, specifically the oil & gas, manufacturing, marine, food & beverage, and commercial markets which includes hospitals, schools, government facilities, etc.
Regarding the merger and integration, Mr. Parrish stated "I am very pleased by the quality, competence, and enthusiasm of the employees of both organizations. As in any integration effort, we will promote the best and brightest while consolidating and minimizing the redundant pieces within the next 90 days to control costs. Equisol brings needed sales, services, and geographic presence to the combined team while Xiom provides the intellectual property, dedicated products, and engineering strength to create a truly consolidated company with reduced dependency upon outside resources. The combination of these two entities establishes a very synergistic environmental services platform focused on our global infrastructure from which we will grow exponentially for many years to come."
About Environmental Infrastructure Holdings Corp.
Environmental Infrastructure Holdings (EIHC) is the parent company of various environmental manufacturing, engineering, and services companies. Currently, EIHC has two subsidiaries Equisol, LLC and Xiom Corp. as well as investments into various joint ventures and partnerships.
Recognized in 2008 by INC Magazine as the 7th fastest growing private Environmental Services Company in America, Equisol, LLC, is a unique equipment solutions provider specializing in the water and wastewater industry. Our team of top rated engineers specializes in automation equipment and services across multiple industries where water use and automation are important. From consulting and design of equipment systems, to sales, installation and maintenance services, Equisol can address our customer's needs in many diverse applications. Equisol provides cost effective equipment strategies to allow users of water and producers of wastewater to achieve profitability while focusing on their core business activities. Through our association with world technology leaders, we are able to supply a broad spectrum of high quality products. Our staff, with over 300 years of engineering experience in equipment automation, uses these technologies to select the most effective solution for our customer's applications. Other recognition that Equisol has achieved include the Entrepreneur Hot 100 Fastest New Companies in 2004, INC5000 ranking of #621 for 2007, and 2009 Philadelphia 100 recognizing the fastest growing private companies in the region.
Xiom Corp. is a technology business offering delivery of plastic powder coatings at on-site locations utilizing the XIOM 1000 System. Powder coating currently is a process in which metal parts are brought into a factory environment where they are cleaned and prepared to receive a powder coating. Plastic in powder form is then applied to the various metal parts by means of an electrostatic charge that causes the powder to adhere to the surface. The coated part is then heated in an oven for a period of time to cause the plastic to melt and adhere to the substrate. Although we use plastic powder, we do not electro-statically charge that powder in order for it to adhere to a substrate. We use a different mechanism which simultaneously applies and fuses the powder to a substrate. The advantage of this process is that the coating process is totally portable and can be applied anywhere, not necessarily in a factory setting, and can be applied without use of an oven to cure the coating, and can be applied to most substrates in addition to the metal substrate to which powder coatings are traditionally applied in a factory, using an oven.
disclaimer: www.undiscoveredequities.com/disclaimer_x.html
Monday, December 7, 2009
Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx - Over-the-Counter and Prescription Treatments for Chronic Pain (OTCBB:NPHC)
Nutra Pharma Has Completed Submission of the Final Nyloxin OTC and Nyloxin Rx Packaging and Labeling to the Food and Drug Administration (FDA). This Registration is Considered the Final Step Required by the FDA to Begin Selling Nyloxin OTC and Nyloxin Rx in the United States for the Treatment of Chronic Pain.
Press Release Source: Nutra Pharma Corp. On 9:03 am EST, Monday December 7, 2009
PLANTATION, Fla.--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Nyloxin OTC, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, a prescription treatment for severe (Stage 3) chronic pain.
“Completing the FDA registration for Nyloxin OTC and Nyloxin Rx is an important and required step towards introducing our Nyloxin-branded pain relievers throughout domestic and international markets,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “With the FDA registration now completed, we plan to immediately move forward with our launch of Nyloxin Rx here in the United States, while we finalize our international drug registrations in Canada, Europe and South America for both our prescription and over-the-counter formulations,” he concluded.
The Company first introduced Nyloxin OTC in November as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC is similar to the Company’s recently launched pain reliever, Cobroxin, and will be available internationally as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additionally, the Company introduced Nyloxin Rx in October as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.
Both Nyloxin OTC and Nyloxin Rx are produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, and do not rely on the use of opioids or acetaminophen for their pain relieving action.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Nyloxin.com
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Thursday, December 3, 2009
Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain (OTCBB:NPHC)
Nutra Pharma will be conducting a webinar on December 10, 2009, to discuss the Company's over-the-counter and prescription treatments for chronic pain, Cobroxin and Nyloxin Rx
PLANTATION, Fla., Dec 03, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company's treatments for chronic pain.
"Over the past few months, we have been gaining traction in the pain market through the launch of our over-the-counter pain reliever, Cobroxin, and our recently introduced prescription pain reliever, Nyloxin Rx," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We would like to invite all of our shareholders and other interested parties to join us on this webinar so that we may explain our current progress and our short-term and long-term goals," he added.
Registration is limited. To register for the upcoming webinar, visit http://tinyurl.com/NPHCwebinar.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
http://www.Nyloxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
PLANTATION, Fla., Dec 03, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company's treatments for chronic pain.
"Over the past few months, we have been gaining traction in the pain market through the launch of our over-the-counter pain reliever, Cobroxin, and our recently introduced prescription pain reliever, Nyloxin Rx," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We would like to invite all of our shareholders and other interested parties to join us on this webinar so that we may explain our current progress and our short-term and long-term goals," he added.
Registration is limited. To register for the upcoming webinar, visit http://tinyurl.com/NPHCwebinar.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
http://www.Nyloxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Tuesday, December 1, 2009
Houston American Energy Enters Into Financing (NASDAQ:HUSA)
Press Release Source: Houston American Energy Corp On 8:07 pm EST, Monday November 30, 2009HOUSTON, Nov. 30 / --
Houston American Energy Corp. (Nasdaq: HUSA - News; the "Company"), an independent energy company with interests in oil and natural gas wells and prospects, announced today that it has reached an agreement to place up to 3,000,000 shares of the Company's common stock to select institutional investors at $4.68 per share in a registered direct offering for gross proceeds of approximately $14 million, before deducting placement agents' fees and estimated offering expenses. The transaction is expected to close on or about December 4, 2009, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for general working capital purposes, including funding the Company's share of costs of development of properties in which the Company hold interests.
Global Hunter Securities, LLC acted as lead placement agent and Knight Capital Markets, LLC acted as a co-placement agent for the offering.
A shelf registration statement relating to these securities previously was filed and declared effective by the Securities and Exchange Commission. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. A copy of the base prospectus and prospectus supplement (once filed) can be obtained at the Securities and Exchange Commission's website http://www.sec.gov or from Global Hunter Securities, LLC at 400 Poydras Street, Suite 1510 New Orleans, Louisiana 70130 Attn: Kelly Vest.
About Houston American Energy Corp.
Based in Houston, Texas, Houston American Energy Corp. is an independent energy company with interests in oil and natural gas wells and prospects. The company's business strategy includes a property mix of producing and non-producing assets with a focus on Colombia, Texas, and Louisiana.
Houston American Energy Corp. (Nasdaq: HUSA - News; the "Company"), an independent energy company with interests in oil and natural gas wells and prospects, announced today that it has reached an agreement to place up to 3,000,000 shares of the Company's common stock to select institutional investors at $4.68 per share in a registered direct offering for gross proceeds of approximately $14 million, before deducting placement agents' fees and estimated offering expenses. The transaction is expected to close on or about December 4, 2009, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for general working capital purposes, including funding the Company's share of costs of development of properties in which the Company hold interests.
Global Hunter Securities, LLC acted as lead placement agent and Knight Capital Markets, LLC acted as a co-placement agent for the offering.
A shelf registration statement relating to these securities previously was filed and declared effective by the Securities and Exchange Commission. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. A copy of the base prospectus and prospectus supplement (once filed) can be obtained at the Securities and Exchange Commission's website http://www.sec.gov or from Global Hunter Securities, LLC at 400 Poydras Street, Suite 1510 New Orleans, Louisiana 70130 Attn: Kelly Vest.
About Houston American Energy Corp.
Based in Houston, Texas, Houston American Energy Corp. is an independent energy company with interests in oil and natural gas wells and prospects. The company's business strategy includes a property mix of producing and non-producing assets with a focus on Colombia, Texas, and Louisiana.
Friday, November 27, 2009
Nutra Pharma's (OTCBB:NPHC) Distributor for Cobroxin, XenaCare Holdings, Announces National Sponsorship of the Arthritis Foundation
XenaCare Holdings has announced that it has become a national sponsor of the Arthritis Foundation, one of the largest nonprofit organizations dedicated to arthritis research and public health education.
Delray Beach, FL. – November 27, 2009 – XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.
“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.
With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.
The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:
• Advocacy - Local, state and national efforts to advance vital legislation.
• Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
• Public health - Information and empowering programs and services.
• Community-based outreach - Network of 42 chapter offices
Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex™, Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.
In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.
About XenaCare HoldingsXenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
Benefits to Cobroxin include:
• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting
The Company’s additional clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. The Company also offers formulations for the lifestyle performance market, which consists of sports line for athletes, including the SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays.
http://www.Nutrapharma.com
http://www.Cobroxin.com
Kevin McKnight
800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Delray Beach, FL. – November 27, 2009 – XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.
“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.
With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.
The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:
• Advocacy - Local, state and national efforts to advance vital legislation.
• Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
• Public health - Information and empowering programs and services.
• Community-based outreach - Network of 42 chapter offices
Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex™, Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.
In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.
About XenaCare HoldingsXenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
Benefits to Cobroxin include:
• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting
The Company’s additional clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. The Company also offers formulations for the lifestyle performance market, which consists of sports line for athletes, including the SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays.
http://www.Nutrapharma.com
http://www.Cobroxin.com
Kevin McKnight
800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Monday, November 23, 2009
Manas (OTCBB: MNAP) Enters Into Letter of Intent to Sell A Portion of Its Interest in Its Albanian Project
BAAR, SWITZERLAND, November 23rd, 2009.
Manas Petroleum (“Manas”) (OTCBB: MNAP) is pleased to report that it has entered into an arm’s length binding letter of intent (the "LOI") dated November 19, 2009 with WWI Resources ("WWI") a TSX-V listed company, pursuant to which Manas will sell all of the shares of one of its wholly-owned subsidiaries (the “Subsidiary”) in exchange for a minimum of 100,000,000 common shares and a signing bonus in cash. At or prior to closing, Manas will reorganize its affairs such that the Subsidiary will own 100% of Manas’ Albanian assets. The LOI provides that, after closing, WWI will be obligated to issue to Manas up to an aggregate of 150,000,000 additional WWI common shares upon the achievement of certain operational targets.
Completion of the transaction is subject to, among other things, completion of due diligence satisfactory to both parties, execution of a definitive agreement, receipt of all necessary regulatory and shareholder approvals and completion of a private placement in which WWI will sell 100,000,000 units at a price of $0.25 per unit for gross proceeds of (Cdn) $25,000,000. Each unit will consist of one common share and one warrant, with each warrant entitling the holder to purchase a further common share at a price of (Cdn) $ 0.45 per share for a period of 5 years from closing. At closing, each of WWI and Manas will appoint 3 directors to the board of WWI and the current officers of Manas will be appointed as officers of WWI. At closing, the Subsidiary will hold three Production Sharing Contracts (PSCs) onshore Blocks in Albania that comprise 1.7 million net acres with 100% working interest. The PSCs are for Blocks A, B, D, E and for Blocks 2 & 3. There have been nine large structures identified in Blocks A, B, D & E and three structures on Blocks 2 & 3. It is important to note that Block 2 is within the area where Bankers Petroleum’s (BNK.TO) current shallow oil production derives from. Manas has the right to explore and produce oil from the deeper targets. In 2001, the Shpiragu 1 well was drilled by Occidental petroleum in Block 2. The Shpiragu-1 well averaged 400 -1,200 bbl/d of light oil, confirming an active hydrocarbon system. There are no known reserves on any of these properties.
Eric Herlyn, Chief Executive Officer of Manas Petroleum, comments, “We believe this is an excellent transaction for Manas as it will create significant shareholder value moving forward. This transaction is consistent with Manas’ core strategy of acquiring high impact oil and gas licenses and then limiting the financial burdens and risks associated with the exploration and development.” A more extensive press release will be out shortly which will provide more details of the transaction.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real S, Ste 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Manas Petroleum (“Manas”) (OTCBB: MNAP) is pleased to report that it has entered into an arm’s length binding letter of intent (the "LOI") dated November 19, 2009 with WWI Resources ("WWI") a TSX-V listed company, pursuant to which Manas will sell all of the shares of one of its wholly-owned subsidiaries (the “Subsidiary”) in exchange for a minimum of 100,000,000 common shares and a signing bonus in cash. At or prior to closing, Manas will reorganize its affairs such that the Subsidiary will own 100% of Manas’ Albanian assets. The LOI provides that, after closing, WWI will be obligated to issue to Manas up to an aggregate of 150,000,000 additional WWI common shares upon the achievement of certain operational targets.
Completion of the transaction is subject to, among other things, completion of due diligence satisfactory to both parties, execution of a definitive agreement, receipt of all necessary regulatory and shareholder approvals and completion of a private placement in which WWI will sell 100,000,000 units at a price of $0.25 per unit for gross proceeds of (Cdn) $25,000,000. Each unit will consist of one common share and one warrant, with each warrant entitling the holder to purchase a further common share at a price of (Cdn) $ 0.45 per share for a period of 5 years from closing. At closing, each of WWI and Manas will appoint 3 directors to the board of WWI and the current officers of Manas will be appointed as officers of WWI. At closing, the Subsidiary will hold three Production Sharing Contracts (PSCs) onshore Blocks in Albania that comprise 1.7 million net acres with 100% working interest. The PSCs are for Blocks A, B, D, E and for Blocks 2 & 3. There have been nine large structures identified in Blocks A, B, D & E and three structures on Blocks 2 & 3. It is important to note that Block 2 is within the area where Bankers Petroleum’s (BNK.TO) current shallow oil production derives from. Manas has the right to explore and produce oil from the deeper targets. In 2001, the Shpiragu 1 well was drilled by Occidental petroleum in Block 2. The Shpiragu-1 well averaged 400 -1,200 bbl/d of light oil, confirming an active hydrocarbon system. There are no known reserves on any of these properties.
Eric Herlyn, Chief Executive Officer of Manas Petroleum, comments, “We believe this is an excellent transaction for Manas as it will create significant shareholder value moving forward. This transaction is consistent with Manas’ core strategy of acquiring high impact oil and gas licenses and then limiting the financial burdens and risks associated with the exploration and development.” A more extensive press release will be out shortly which will provide more details of the transaction.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real S, Ste 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Thursday, November 19, 2009
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution (OTCBB: NPHC)
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution (OTCBB: NPHC)
Nov 19, 2009 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC (http://www.nyloxin.com/) will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx. "Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm (http://www.receptopharm.com/). "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.
Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.
"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma (http://www.nutrapharma.com/). "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.
Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
About Nutra Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.nyloxin.com
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Nov 19, 2009 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC (http://www.nyloxin.com/) will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx. "Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm (http://www.receptopharm.com/). "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.
Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.
"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma (http://www.nutrapharma.com/). "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.
Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
About Nutra Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.nyloxin.com
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Thursday, November 12, 2009
Houston American Energy Investor Presentation
Company Overview
Houston American Energy Corp (NASDAQ:HUSA), the “Company”, is a growth-oriented independent energy company engaged in the exploration, development and production of crude oil and natural gas resources
Operations focused in Colombia
•Current production of approximately 850 barrels of oil equivalent per day•Participated in drilling of 100 wells in Colombia to date•Developing new international projects with a focus on Colombia, Peru and Brazil
Significant concessions in Colombia with substantial drilling inventory identified by advanced 3-D seismic interpretation
•Over 895,000 gross acres with more than 100 currently identified drilling prospects
Investment Opportunity
Unique portfolio of high impact, large reserve potential projects in Colombia•Pure-play small cap oil focused investment opportunity with substantial upside potential•Significant acreage position focused in the Llanos Basin in Colombia•Favorable government royalties and fiscal terms on existing contracts
Significant Technical Partner with SK Energy, a leading Asian integrated oil and gas company
Proven Track Record
•Participating in successful drilling program led by Hupecol•Drilled 100 wells in Colombia with a 70% success rate to date•With approximately $19.8MM in invested capital management has generated in excess of $112.0MM of market capital to date
Low cost structure•Non-operator strategy allows for minimal corporate staff•Colombian properties have lower finding and development costs versus U.S. conventional and unconventional reserves
Experienced management and board of directors with access to proprietary deal flow
Simple capitalization structure
Business Strategy
Explore and develop existing properties through the drill bit•Increase production and cash flow by drilling and completing identified well locations•Quantify value of our asset base through an aggressive testing and drilling program•Explore for and develop additional proved reserves on approximately 150,000 net acres
Acquire additional interest in oil and gas properties through partnerships and joint ventures with experienced operators•Target acquisitions that enhance our core areas•Focus on high impact, lower risk drilling prospects
Capitalize on the expertise, experience and strategic relationships of the management team and board of directors
For a full presentation on Houston American Energy Group click here
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Houston American Energy Corp (NASDAQ:HUSA), the “Company”, is a growth-oriented independent energy company engaged in the exploration, development and production of crude oil and natural gas resources
Operations focused in Colombia
•Current production of approximately 850 barrels of oil equivalent per day•Participated in drilling of 100 wells in Colombia to date•Developing new international projects with a focus on Colombia, Peru and Brazil
Significant concessions in Colombia with substantial drilling inventory identified by advanced 3-D seismic interpretation
•Over 895,000 gross acres with more than 100 currently identified drilling prospects
Investment Opportunity
Unique portfolio of high impact, large reserve potential projects in Colombia•Pure-play small cap oil focused investment opportunity with substantial upside potential•Significant acreage position focused in the Llanos Basin in Colombia•Favorable government royalties and fiscal terms on existing contracts
Significant Technical Partner with SK Energy, a leading Asian integrated oil and gas company
Proven Track Record
•Participating in successful drilling program led by Hupecol•Drilled 100 wells in Colombia with a 70% success rate to date•With approximately $19.8MM in invested capital management has generated in excess of $112.0MM of market capital to date
Low cost structure•Non-operator strategy allows for minimal corporate staff•Colombian properties have lower finding and development costs versus U.S. conventional and unconventional reserves
Experienced management and board of directors with access to proprietary deal flow
Simple capitalization structure
Business Strategy
Explore and develop existing properties through the drill bit•Increase production and cash flow by drilling and completing identified well locations•Quantify value of our asset base through an aggressive testing and drilling program•Explore for and develop additional proved reserves on approximately 150,000 net acres
Acquire additional interest in oil and gas properties through partnerships and joint ventures with experienced operators•Target acquisitions that enhance our core areas•Focus on high impact, lower risk drilling prospects
Capitalize on the expertise, experience and strategic relationships of the management team and board of directors
For a full presentation on Houston American Energy Group click here
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain RelieverNutra Pharma has announced its intention to begin the drug registration process in Brazil and Colombia for its over-the-counter pain reliever. The company is currently marketing a similar analgesic, Cobroxin, in the United States for the treatment of moderate to severe (Stage 2) chronic pain.
Press Release Source: Nutra Pharma Corp. On 9:03 am EST, Thursday November 12, 2009PLANTATION, Fla.--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.
“Beginning the drug registration process in Brazil and Colombia offers us the opportunity to introduce our over-the-counter pain reliever into countries that have significant portions of their populations suffering from chronic pain, but lack sufficient access to opioid-based analgesics,” explained Dr. Paul Reid, CEO of ReceptoPharm. “We have already begun conversations with potential South American licensees and plan to initiate the drug registration process in both countries as we move into 2010,” he added.
Nutra Pharma introduced a similar pain medicine in the United States in August under the brand Cobroxin. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
“We are excited to begin the drug registration process in Brazil and Colombia, as these two countries make up approximately 60% of the population of South America and represent the most important entry-points for launching our pain reliever into the entire South American market,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “While we complete our drug registration in Brazil and Colombia, we plan to continue building our international presence by registering our pain drug in additional countries worldwide,” he concluded.
In September, Nutra Pharma announced its intention to begin drug registration for its pain reliever in Canada and Europe. Given the existing regulatory requirements in these territories, the Company expects to complete these registrations in the near-term.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Press Release Source: Nutra Pharma Corp. On 9:03 am EST, Thursday November 12, 2009PLANTATION, Fla.--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.
“Beginning the drug registration process in Brazil and Colombia offers us the opportunity to introduce our over-the-counter pain reliever into countries that have significant portions of their populations suffering from chronic pain, but lack sufficient access to opioid-based analgesics,” explained Dr. Paul Reid, CEO of ReceptoPharm. “We have already begun conversations with potential South American licensees and plan to initiate the drug registration process in both countries as we move into 2010,” he added.
Nutra Pharma introduced a similar pain medicine in the United States in August under the brand Cobroxin. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
“We are excited to begin the drug registration process in Brazil and Colombia, as these two countries make up approximately 60% of the population of South America and represent the most important entry-points for launching our pain reliever into the entire South American market,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “While we complete our drug registration in Brazil and Colombia, we plan to continue building our international presence by registering our pain drug in additional countries worldwide,” he concluded.
In September, Nutra Pharma announced its intention to begin drug registration for its pain reliever in Canada and Europe. Given the existing regulatory requirements in these territories, the Company expects to complete these registrations in the near-term.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Monday, November 9, 2009
HOUSTON AMERICAN ENERGY (Nasdaq: HUSA) ANNOUNCES THIRD QUARTER 2009 FINANCIAL RESULTS -- Company Declares Quarterly Dividend of $.005 per Share
Houston, Texas - November 6, 2009 - Houston American Energy Corp. (Nasdaq: HUSA) yesterday reported its financial results for the quarter ended September 30, 2009.
The Company reported net income for the three months ended September 30, 2009 of $428,578, or $0.02 per share, on revenues of $2,403,996, as compared to net income of $798,832, or $0.03 per share, on revenues of $2,350,782 for the three months ended September 30, 2008. For the nine months ended September 30, 2009, the company reported a loss of $937,634, or $0.03 per share, on revenue of $3,983,256, as compared to net income of $4,870,356, or $0.17 per diluted share, on revenues of $8,616,868. The increase in revenue for the quarter was primarily attributable to increased volumes in our Colombia operations, offset by decreased commodity prices realized in the 2009 quarter as compared to 2008. The decrease in revenue for the nine months ended September 30, 2009 was primarily attributable to reduced production from the majority of our wells being shut in during the later half of the 1st quarter and early in the 2nd quarter of 2009, and lost production related to the sale of the Caracara concession in 2008. Mr. John F. Terwilliger, President and Chairman of Houston American Energy, stated, Houston American Energy's production volumes sold in the third quarter showed an 80% improvement over the second quarter and a 46% improvement versus the volumes sold during the third quarter of 2008. We expect this trend to continue into the fourth quarter as production volumes have been strong and are expected to stay strong going forward. The next six months should be very eventful for Houston American Energy as we expect to commence drilling on one of our new blocks in Colombia. In addition, during this period we should have the results of the sales process of a portion of our Colombian assets as described in our Form 8-K filed on September 23, 2009, which we believe will provide significant additional liquidity to the Company. These are exciting times for Houston American Energy as we are embarking on a new and potentially very significant growth phase for the Company.
In view of the Board of Directors' confidence in the outlook for Houston American Energy, a dividend of $0.005 per share has been declared for shareholders of record as of December 1, 2009 with a payment date of December 17, 2009.
About Houston American Energy Corp.
Based in Houston, Texas, Houston American Energy Corp. is an independent energy company with interests in oil and natural gas wells and prospects. The company's business strategy includes a property mix of producing and non-producing assets with a focus on Texas, Louisiana and Colombia. Additional information can be accessed by reviewing our Form 10-Q and other periodic reports filed with the Securities and Exchange Commission which can be found on our website at www.houstonamericanenergy.com.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
disclaimer
The Company reported net income for the three months ended September 30, 2009 of $428,578, or $0.02 per share, on revenues of $2,403,996, as compared to net income of $798,832, or $0.03 per share, on revenues of $2,350,782 for the three months ended September 30, 2008. For the nine months ended September 30, 2009, the company reported a loss of $937,634, or $0.03 per share, on revenue of $3,983,256, as compared to net income of $4,870,356, or $0.17 per diluted share, on revenues of $8,616,868. The increase in revenue for the quarter was primarily attributable to increased volumes in our Colombia operations, offset by decreased commodity prices realized in the 2009 quarter as compared to 2008. The decrease in revenue for the nine months ended September 30, 2009 was primarily attributable to reduced production from the majority of our wells being shut in during the later half of the 1st quarter and early in the 2nd quarter of 2009, and lost production related to the sale of the Caracara concession in 2008. Mr. John F. Terwilliger, President and Chairman of Houston American Energy, stated, Houston American Energy's production volumes sold in the third quarter showed an 80% improvement over the second quarter and a 46% improvement versus the volumes sold during the third quarter of 2008. We expect this trend to continue into the fourth quarter as production volumes have been strong and are expected to stay strong going forward. The next six months should be very eventful for Houston American Energy as we expect to commence drilling on one of our new blocks in Colombia. In addition, during this period we should have the results of the sales process of a portion of our Colombian assets as described in our Form 8-K filed on September 23, 2009, which we believe will provide significant additional liquidity to the Company. These are exciting times for Houston American Energy as we are embarking on a new and potentially very significant growth phase for the Company.
In view of the Board of Directors' confidence in the outlook for Houston American Energy, a dividend of $0.005 per share has been declared for shareholders of record as of December 1, 2009 with a payment date of December 17, 2009.
About Houston American Energy Corp.
Based in Houston, Texas, Houston American Energy Corp. is an independent energy company with interests in oil and natural gas wells and prospects. The company's business strategy includes a property mix of producing and non-producing assets with a focus on Texas, Louisiana and Colombia. Additional information can be accessed by reviewing our Form 10-Q and other periodic reports filed with the Securities and Exchange Commission which can be found on our website at www.houstonamericanenergy.com.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
disclaimer
Wednesday, November 4, 2009
Nutra Pharma's (OTCBB: NPHC) Cobroxin Distributor, XenaCare Holdings Announces Availability of Cobroxin through the Chain Drug Marketing Association
XenaCare Holdings (OTCBB: XCHO) has Announced That the Chain Drug Marketing Association (CDMA) Will Begin Taking Inventory of Cobroxin for Redistribution and Sale Through its 6,000 Member Pharmacies
DELRAY BEACH, Fla., Nov 04, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States. "As one of the largest pharmacy organizations in the United States, we are excited to be working with the CDMA to distribute Cobroxin to its independent pharmacy members," explained Frank Rizzo, President of XenaCare Holdings. "Having a presence in CDMA member pharmacies will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign," he concluded.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- More Potent than Morphine
-- Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About Nutra Pharma:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
DELRAY BEACH, Fla., Nov 04, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States. "As one of the largest pharmacy organizations in the United States, we are excited to be working with the CDMA to distribute Cobroxin to its independent pharmacy members," explained Frank Rizzo, President of XenaCare Holdings. "Having a presence in CDMA member pharmacies will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign," he concluded.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- More Potent than Morphine
-- Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About Nutra Pharma:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Monday, November 2, 2009
Nutra Pharma (OTCBB: NPHC) featured company in Wall Street Transcript
Nutra Pharma (OTCBB: NPHC) featured company in Wall Street Transcript
Rik Deitsch, President, CEO and Director of Nutra Pharma (NPHC) talked to The Wall Street Transcript about his company Nutra Pharma. Click here to read the complete interview.
For the full article please click here: http://www.twst.com/pdf/ANG600.pdf
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Rik Deitsch, President, CEO and Director of Nutra Pharma (NPHC) talked to The Wall Street Transcript about his company Nutra Pharma. Click here to read the complete interview.
For the full article please click here: http://www.twst.com/pdf/ANG600.pdf
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Monday, October 26, 2009
Nutra Pharma (OTCBB: NPHC) Chairman and Chief Executive Officer, Rik J Deitsch, Interviewed by CEOCFO.com
Nutra Pharma (OTCBB: NPHC) Chairman and Chief Executive Officer, Rik J Deitsch, Interviewed by CEOCFO.com
Click Here for Full Article:
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight1-800-404-8982Undiscovered Equities, Inc.1515 S Federal Hwy, Ste 207Boca Raton, FL 33432www.undiscoveredequities.com
Click Here for Full Article:
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight1-800-404-8982Undiscovered Equities, Inc.1515 S Federal Hwy, Ste 207Boca Raton, FL 33432www.undiscoveredequities.com
Thursday, October 22, 2009
NutraPharma's (OTCBB: NPHC) distributor, XenaCare to Market its Over-the-Counter Pain Reliever, Cobroxin, in the Official Annual Publication of NASCAR
XenaCare Holdings Has Announced That It Will Begin Marketing Its Over-the-Counter (OTC) Pain Reliever, Cobroxin, in Racing One, the Official Annual Publication of NASCAR
DELRAY BEACH, Fla., Oct 22, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an agreement to market its over-the-counter (OTC) pain reliever, Cobroxin, in Racing One, the official annual publication of NASCAR, for the 2010 racing season. Cobroxin is currently available online at Cobroxin.com and will be available soon at various retail outlets. The 2010 Racing One Annual, which will be available starting at the 52nd anniversary of the NASCAR Sprint Cup DAYTONA 500 in February 2010, will be sold through the end of the season. In addition to reaching approximately 8.5 million NASCAR fans attending the 78 NASCAR events being held at the 26 NASCAR sanctioned racetracks, the Publication will also be sold throughout North America in major newsstands, bookstores, grocery stores, retail outlets, train stations, and airports.
"We are excited to be advertising Cobroxin in the 2010 Racing One Annual, as it offers us the opportunity to build awareness around Cobroxin by introducing it through NASCAR, the fastest growing spectator sport in the United States," commented Frank Rizzo, President of XenaCare Holdings. "We look forward to beginning this campaign and continuing to expand our marketing efforts as we introduce Cobroxin through retailers across the United States," he added.
In addition to the Company's agreement to market Cobroxin in NASCAR's Racing One, XenaCare Holdings will also be advertising Cobroxin in the 2009 NFL Alumni Guide and Yearbook. Additionally, the Company announced plans to begin its initial print marketing campaign this fall, which includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced on Monday that it had begun accepting orders for Cobroxin online at Cobroxin.com. The Company intends to announce both online and brick-and-mortar retailers in the coming weeks as they begin offering Cobroxin for sale to consumers.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.xenacareholdings.com/
http://www.cobroxin.com/
For More information contact:
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
DELRAY BEACH, Fla., Oct 22, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an agreement to market its over-the-counter (OTC) pain reliever, Cobroxin, in Racing One, the official annual publication of NASCAR, for the 2010 racing season. Cobroxin is currently available online at Cobroxin.com and will be available soon at various retail outlets. The 2010 Racing One Annual, which will be available starting at the 52nd anniversary of the NASCAR Sprint Cup DAYTONA 500 in February 2010, will be sold through the end of the season. In addition to reaching approximately 8.5 million NASCAR fans attending the 78 NASCAR events being held at the 26 NASCAR sanctioned racetracks, the Publication will also be sold throughout North America in major newsstands, bookstores, grocery stores, retail outlets, train stations, and airports.
"We are excited to be advertising Cobroxin in the 2010 Racing One Annual, as it offers us the opportunity to build awareness around Cobroxin by introducing it through NASCAR, the fastest growing spectator sport in the United States," commented Frank Rizzo, President of XenaCare Holdings. "We look forward to beginning this campaign and continuing to expand our marketing efforts as we introduce Cobroxin through retailers across the United States," he added.
In addition to the Company's agreement to market Cobroxin in NASCAR's Racing One, XenaCare Holdings will also be advertising Cobroxin in the 2009 NFL Alumni Guide and Yearbook. Additionally, the Company announced plans to begin its initial print marketing campaign this fall, which includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced on Monday that it had begun accepting orders for Cobroxin online at Cobroxin.com. The Company intends to announce both online and brick-and-mortar retailers in the coming weeks as they begin offering Cobroxin for sale to consumers.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.xenacareholdings.com/
http://www.cobroxin.com/
For More information contact:
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Tuesday, October 20, 2009
NutraPharma's (OTCBB:NPHC) Distributor, XenaCare Holdings Announces Agreement to Market OTC Pain Reliever, Cobroxin, in NFL Alumni Publication
Nutra Pharma's (OTCBB: NPHC) Distributor, XenaCare Holdings Announces Agreement to Market OTC Pain Reliever, Cobroxin, in the National Football League (NFL) Alumni Association Publication
XenaCare Holdings Has Signed an Agreement to Advertise Cobroxin in the 2009 NFL Alumni Guide and Yearbook. The Publication Reaches Hundreds of Thousands of Fans Each Year as Well as Current and Past NFL Players, Team Owners, Coaches and League Executives.
DELRAY BEACH, Fla., Oct 20, 2009 XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an advertising agreement with Belmont International to market its over-the-counter pain reliever, Cobroxin, in the 2009 NFL Alumni Guide and Yearbook. Belmont International is the official publisher of the NFL Alumni Guide and Yearbook. The NFL Alumni Guide and Yearbook reaches hundreds of thousands of NFL fans each year. In addition to its public release, the 2009 Publication will also be released under a controlled distribution to current and past players of the league, team owners, coaches, and league executives.
"We are excited to announce this advertising agreement because the NFL Alumni Association not only represents one of the most prestigious sports organizations in North America, but also because it reaches a demographic that we believe will have a strong interest in our pain reliever, Cobroxin," explained Frank Rizzo, President of XenaCare Holdings. "As we move forward with our national launch, we plan to continue announcing our additional marketing outreach campaigns that are designed to help build awareness around Cobroxin and to support our current online sales at Cobroxin.com as well as sales at retailers, both online and brick-and-mortar, where Cobroxin will soon be available," he concluded.
In August, XenaCare Holdings was granted the exclusive license by Nutra Pharma Corporation (OTCBB:NPHC) to market and distribute Cobroxin throughout the United States. In addition to advertising in the NFL Alumni Guide and Yearbook, XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertisements in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://app.streamsend.com/c/6757341/721/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.XenaCareHoldings.com http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://app.streamsend.com/c/6757341/725/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.undiscoveredequities.com
XenaCare Holdings Has Signed an Agreement to Advertise Cobroxin in the 2009 NFL Alumni Guide and Yearbook. The Publication Reaches Hundreds of Thousands of Fans Each Year as Well as Current and Past NFL Players, Team Owners, Coaches and League Executives.
DELRAY BEACH, Fla., Oct 20, 2009 XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an advertising agreement with Belmont International to market its over-the-counter pain reliever, Cobroxin, in the 2009 NFL Alumni Guide and Yearbook. Belmont International is the official publisher of the NFL Alumni Guide and Yearbook. The NFL Alumni Guide and Yearbook reaches hundreds of thousands of NFL fans each year. In addition to its public release, the 2009 Publication will also be released under a controlled distribution to current and past players of the league, team owners, coaches, and league executives.
"We are excited to announce this advertising agreement because the NFL Alumni Association not only represents one of the most prestigious sports organizations in North America, but also because it reaches a demographic that we believe will have a strong interest in our pain reliever, Cobroxin," explained Frank Rizzo, President of XenaCare Holdings. "As we move forward with our national launch, we plan to continue announcing our additional marketing outreach campaigns that are designed to help build awareness around Cobroxin and to support our current online sales at Cobroxin.com as well as sales at retailers, both online and brick-and-mortar, where Cobroxin will soon be available," he concluded.
In August, XenaCare Holdings was granted the exclusive license by Nutra Pharma Corporation (OTCBB:NPHC) to market and distribute Cobroxin throughout the United States. In addition to advertising in the NFL Alumni Guide and Yearbook, XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertisements in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://app.streamsend.com/c/6757341/721/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.XenaCareHoldings.com http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://app.streamsend.com/c/6757341/725/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.undiscoveredequities.com
Wednesday, October 14, 2009
BUYINS.NET Issues Nutra Pharma SqueezeTrigger Report Approximately 12.92 Million Shares Shorted Since January 2005 (OTCBB: NPHC)
Press Release Source: BUYINS.NET
On 1:14 pm EDT, Wednesday October 14, 2009
NEWPORT BEACH, Calif., Oct. 14, 2009
http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTCBB:NPHC - News) after releasing the latest short sale data to July 2009. From January 2005 to October 2009, approximately 167.8 million total aggregate shares of NPHC have traded for a total dollar value of nearly $46.7 million. The total aggregate number of shares shorted in this time period is approximately 12.92 million shares. The NPHC SqueezeTrigger price of $0.28 is the volume weighted average short price of all short selling in NPHC. A series of short squeezes has begun as shares of NPHC have jumped from $0.03 to a recent high of $0.99. With the stock at $0.51 currently, 69% of all shares shorted in NPHC are now out-of-the-money. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net/.
A detailed NPHC report is at: http://www.buyins.com/reports/nphc10-10-09.pdf
Click here to view SqueezeTrigger: http://www.buyins.com/images/nphcstr10-14-09.jpg
Click here to view Friction Factor: http://www.buyins.com/images/nphcff10-10-09.jpg
Friction Factor is used to calculate if a fair market is being made in the shares of NPHC. 60% of recent trading days are positive or bullishly-biased and 40% of trading days are negative or bearishly biased. Days where trading was abnormal shows 100% bullish and 0% bearish biases, which means that there is a bullishly-biased market being made in NPHC in the past 32 trading days.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
On 1:14 pm EDT, Wednesday October 14, 2009
NEWPORT BEACH, Calif., Oct. 14, 2009
http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTCBB:NPHC - News) after releasing the latest short sale data to July 2009. From January 2005 to October 2009, approximately 167.8 million total aggregate shares of NPHC have traded for a total dollar value of nearly $46.7 million. The total aggregate number of shares shorted in this time period is approximately 12.92 million shares. The NPHC SqueezeTrigger price of $0.28 is the volume weighted average short price of all short selling in NPHC. A series of short squeezes has begun as shares of NPHC have jumped from $0.03 to a recent high of $0.99. With the stock at $0.51 currently, 69% of all shares shorted in NPHC are now out-of-the-money. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net/.
A detailed NPHC report is at: http://www.buyins.com/reports/nphc10-10-09.pdf
Click here to view SqueezeTrigger: http://www.buyins.com/images/nphcstr10-14-09.jpg
Click here to view Friction Factor: http://www.buyins.com/images/nphcff10-10-09.jpg
Friction Factor is used to calculate if a fair market is being made in the shares of NPHC. 60% of recent trading days are positive or bullishly-biased and 40% of trading days are negative or bearishly biased. Days where trading was abnormal shows 100% bullish and 0% bearish biases, which means that there is a bullishly-biased market being made in NPHC in the past 32 trading days.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain (OTCBB: NPHC)
Nutra Pharma’s Over-the-Counter Treatment for Moderate to Severe Chronic Pain, Cobroxin, is Now Available for Sale Online at Cobroxin.com. The Company Plans to Announce Additional Retail Partnerships as Its Moves Through the Fourth Quarter of 2009 and into the First Quarter of 2010.
Press Release Source: Nutra Pharma Corp. On 9:00 am EDT, Wednesday October 14, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
•All Natural
•Non-Addictive
•Non-Narcotic
•Non-Opiate
•More Potent than Morphine
•Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO - News) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Contact:Kevin McKnight
1-800-404-8982
1515 S Federal Hwy STE 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Press Release Source: Nutra Pharma Corp. On 9:00 am EDT, Wednesday October 14, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
•All Natural
•Non-Addictive
•Non-Narcotic
•Non-Opiate
•More Potent than Morphine
•Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO - News) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Contact:Kevin McKnight
1-800-404-8982
1515 S Federal Hwy STE 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Wednesday, October 7, 2009
Nutra Pharma (OTCBB: NPHC) Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
Nyloxin Rx, which Was Developed by Nutra Pharma’s Drug Discovery Subsidiary, ReceptoPharm, Is a Prescription Medicine Launching in Late-2009 for the Treatment of Severe (Stage 3) Chronic Pain.
Press Release Source: Nutra Pharma Corp. On 7:30 am EDT, Wednesday October 7, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.
Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.
“For the past 10 years, we have allocated significant time and resources to the study of peptides from cobra venom for the treatment of several indications, including pain,” explained Dr. Paul Reid, CEO of ReceptoPharm. “Given the amount of clinical evidence using cobra venom as a pain reliever, the drug’s well-defined safety profile, and the active pharmaceutical ingredient, which is a monographed drug under United States Homeopathic Pharmacopoeia, we plan to go directly to market with Nyloxin Rx and begin introducing it to physicians later this year,” he added.
According to a report published by IMS Health, there were a total of 237 million U.S. opioid prescriptions in 2008 with over 85 million prescriptions specifically for the treatment of chronic pain. Additionally, a December 2008 article in the Journal Gazette reported that sales of Oxycodone (not including Percodan) totaled $2.89 billion and that sales of Fentanyl totaled $1.55 billion from January to October of the same year.
“We are excited to be launching Nyloxin Rx as a prescription pain reliever at a time when both physicians and patients are actively looking for alternatives to opioid-based pain therapies. We are confident that Nyloxin Rx will compete successfully with other prescription pain medicines and become the preferred treatment for severe chronic pain,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “While we continue to focus on bringing Nyloxin Rx to market, we are also planning to use our financial and strategic resources to begin additional human clinical trials in the near-term for our other drug indications outside of pain,” he concluded.
For more information go to http://www.nyloxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Nyloxin Rx, which Was Developed by Nutra Pharma’s Drug Discovery Subsidiary, ReceptoPharm, Is a Prescription Medicine Launching in Late-2009 for the Treatment of Severe (Stage 3) Chronic Pain.
Press Release Source: Nutra Pharma Corp. On 7:30 am EDT, Wednesday October 7, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.
Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.
“For the past 10 years, we have allocated significant time and resources to the study of peptides from cobra venom for the treatment of several indications, including pain,” explained Dr. Paul Reid, CEO of ReceptoPharm. “Given the amount of clinical evidence using cobra venom as a pain reliever, the drug’s well-defined safety profile, and the active pharmaceutical ingredient, which is a monographed drug under United States Homeopathic Pharmacopoeia, we plan to go directly to market with Nyloxin Rx and begin introducing it to physicians later this year,” he added.
According to a report published by IMS Health, there were a total of 237 million U.S. opioid prescriptions in 2008 with over 85 million prescriptions specifically for the treatment of chronic pain. Additionally, a December 2008 article in the Journal Gazette reported that sales of Oxycodone (not including Percodan) totaled $2.89 billion and that sales of Fentanyl totaled $1.55 billion from January to October of the same year.
“We are excited to be launching Nyloxin Rx as a prescription pain reliever at a time when both physicians and patients are actively looking for alternatives to opioid-based pain therapies. We are confident that Nyloxin Rx will compete successfully with other prescription pain medicines and become the preferred treatment for severe chronic pain,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “While we continue to focus on bringing Nyloxin Rx to market, we are also planning to use our financial and strategic resources to begin additional human clinical trials in the near-term for our other drug indications outside of pain,” he concluded.
For more information go to http://www.nyloxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Monday, October 5, 2009
Manas Petroleum founder Heinz Scholz and CEO Erik Herlyn are interviewed by Cash.ch
Swiss based Manas petroleum (OTCBB: MNAP) has the chance to become a large player in the petroleum businesses. This exploration Company has drilling rights for gigantic oil reserves. Supervisory board president and founder Heinz Scholz and CEO Erik Herlyn are interviewed by Cash.ch.
Schulz and Herlyn want to build Manas Petroleum into what "World Finance" last year simply stated "the next large oil group".
Follow this link to the full story: http://www.prweb.com/releases/manas/albania/prweb2992524.htm
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Schulz and Herlyn want to build Manas Petroleum into what "World Finance" last year simply stated "the next large oil group".
Follow this link to the full story: http://www.prweb.com/releases/manas/albania/prweb2992524.htm
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Online Financial Publication, CEO-CFO, Interviews Nutra Pharma Chairman and CEO (OTCBB: NPHC)
Online Financial Publication, CEO-CFO, Interviews Nutra Pharma Chairman and CEO (OTCBB: NPHC) - Nutra Pharma Has Announced That Its Chairman and CEO, Rik J. Deitsch, Was Interviewed by the Senior Editor of CEO-CFO, Lynn Fosse. the Interview, Which Will Be Published in Late-October, Focuses on Nutra Pharma's Launch of Its Pain Reliever, Cobroxin, and the Company's Growth Strategies
Press Release Source: Nutra Pharma Corp.
On Monday October 5, 2009, 9:00 am EDT PLANTATION, Fla.-- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J. Deitsch, has completed an interview with leading online financial publication, CEO-CFO.
In the interview, Mr. Deitsch discusses the launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm. Additionally, Mr. Deitsch also discusses the company's growth strategy as it relates to future potential acquisitions and out-licensing partnerships.
"It is a very exciting time for Nutra Pharma. As the company realizes its first significant revenues through the sale of our drug products, it is more important than ever that we share the story of Nutra Pharma with our investors and the public," explained Mr. Deitsch. "As excitement builds around the launch of Cobroxin and the development of our other leading drug indications, we plan to extend our communication outreach to include consumer-oriented media outlets in addition to financial industry publications," he concluded.
CEO-CFO is a weekly online financial publication that combines news and interviews from key executives at publicly-traded companies and venture capital firms in the United States and abroad. The interview with Mr. Deitsch is scheduled for publication in late-October. Once the interview is published on CEO-CFO, a direct link will be made available on the Nutra Pharma website.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
disclaimer: http://www.undiscoveredequities.com/disclaimer_np.html
CONTACT: Kevin McKnight
Undiscovered Equities, Inc
Tel: +1 800 404 8982
WWW: http://www.undiscoveredequities.com
Press Release Source: Nutra Pharma Corp.
On Monday October 5, 2009, 9:00 am EDT PLANTATION, Fla.-- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J. Deitsch, has completed an interview with leading online financial publication, CEO-CFO.
In the interview, Mr. Deitsch discusses the launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm. Additionally, Mr. Deitsch also discusses the company's growth strategy as it relates to future potential acquisitions and out-licensing partnerships.
"It is a very exciting time for Nutra Pharma. As the company realizes its first significant revenues through the sale of our drug products, it is more important than ever that we share the story of Nutra Pharma with our investors and the public," explained Mr. Deitsch. "As excitement builds around the launch of Cobroxin and the development of our other leading drug indications, we plan to extend our communication outreach to include consumer-oriented media outlets in addition to financial industry publications," he concluded.
CEO-CFO is a weekly online financial publication that combines news and interviews from key executives at publicly-traded companies and venture capital firms in the United States and abroad. The interview with Mr. Deitsch is scheduled for publication in late-October. Once the interview is published on CEO-CFO, a direct link will be made available on the Nutra Pharma website.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
disclaimer: http://www.undiscoveredequities.com/disclaimer_np.html
CONTACT: Kevin McKnight
Undiscovered Equities, Inc
Tel: +1 800 404 8982
WWW: http://www.undiscoveredequities.com
Monday, September 21, 2009
Nutra Pharma (OTCBB:NPHC) Announces Plans to Begin Drug Registration Process in Canada and Europe for its Over-the-Counter Pain Reliever
September 21, 2009
Nutra Pharma has announced its intention to begin the registration process in Canada and Europe for its over-the-counter pain reliever. The company is currently marketing a similar analgesic, Cobroxin, in the United States for the treatment of moderate to severe (Stage 2) chronic pain.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.
“We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe,” commented Dr. Paul Reid, CEO of ReceptoPharm. “We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those territories,” he added.
According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reported that chronic pain is a widespread problem, effecting one in five adults across Europe.
“With populations exceeding 33 million people in Canada and over 830 million people throughout Europe, the combined size of the pain market in these countries potentially exceeds that of the United States,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “As we move forward with the registration process in Canada and Europe, we also plan to continue seeking qualified licensing partners to market and distribute our pain reliever worldwide,” he concluded.
In August, Nutra Pharma introduced Cobroxin, the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available in October as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. Additionally, the company recently completed a licensing agreement that grants XenaCare Holdings the exclusive marketing and distribution rights to Cobroxin within the United States.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to http://www.undiscoveredequities.com/ and join our email list on our home page.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Nutra Pharma has announced its intention to begin the registration process in Canada and Europe for its over-the-counter pain reliever. The company is currently marketing a similar analgesic, Cobroxin, in the United States for the treatment of moderate to severe (Stage 2) chronic pain.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.
“We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe,” commented Dr. Paul Reid, CEO of ReceptoPharm. “We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those territories,” he added.
According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reported that chronic pain is a widespread problem, effecting one in five adults across Europe.
“With populations exceeding 33 million people in Canada and over 830 million people throughout Europe, the combined size of the pain market in these countries potentially exceeds that of the United States,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “As we move forward with the registration process in Canada and Europe, we also plan to continue seeking qualified licensing partners to market and distribute our pain reliever worldwide,” he concluded.
In August, Nutra Pharma introduced Cobroxin, the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available in October as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. Additionally, the company recently completed a licensing agreement that grants XenaCare Holdings the exclusive marketing and distribution rights to Cobroxin within the United States.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to http://www.undiscoveredequities.com/ and join our email list on our home page.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Thursday, September 17, 2009
Manas Petroleum (OTCBB: MNAP) Reports Drilling Activity in Huday Nazar Prospect Is On Track
Press Release Source: Manas Petroleum Corp. On Thursday September 17, 2009, 5:46 am EDTBAAR, SWITZERLAND--(09/17/09) - Manas Petroleum (OTC.BB:MNAP) reports on the drilling progress of its second, deeper exploration well at the Huday Nazar SPC-1 (Soh License) Prospect with Santos International Pty. Ltd its Australian-based fellow Shareholders of SPC.
Drilling activity has reached currently a depth of 1970m and drilling is going ahead for additional 430m to the target depth of 2400m.
As the drilling program continues, the partners anticipate interesting intervals in subsequent hole sections, where primary objective reservoirs are interpreted to occur between 1680m and 2400m below ground level which is total well depth. The Prospect was generated as a result of the processing of seismic shot in a recent 2D seismic program by SPC. (South Petroleum Company)
The Huday Nazar replaces the previously planned drilling of the smaller and shallower East Chongora Prospect, which is also in the Soh License area. Acquisition of a total of 800 km of 2D seismic within the SPC licenses was completed as of late May, 2009 and seismic processing and interpretation is ongoing as part of a $ 54 million USD seismic, appraisal and drilling program undertaken by Santos International Pty. Ltd. Santos has the option to discontinue the program after drilling of the second well. Manas Petroleum has a 20% interest in the fully carried exploration program. Preparations by South Petroleum Company are underway for a deep drilling program expected to commence during the first half of 2010. Manas Petroleum's wholly-owned subsidiary, DWM Petroleum AG is the legal and beneficial owner of 25% of the issued share capital of South Petroleum Company, (SPC).
About Manas Petroleum:
Manas Petroleum is an international oil and gas company, focusing on activities in South-Eastern Europe, Central Asia and South America. In Albania, Manas has developed a large exploration project with a total resource potential (P50) of 3 billion barrels (Gustavson, 2008). Four blocks are now drill-ready. The council of ministers recently ratified the production-sharing contract on two bocks to DWM Petroleum, a subsidiary of Manas. A 51-101-compliant estimate is now being prepared. In Kyrgyzstan, Manas has signed a $ 54 million USD farm-out agreement with Santos LTD ADR, covering 1.2 billion barrels in place (Scott Pickford, 2005). Drilling is currently underway. Manas' Development of its license in Tajikistan is now covered by an option farm-in agreement with Santos LTD ADR, where a seismic program has been recently completed. In Chile, Manas and its U.S. partner, IPR, farmed out a large natural gas exploration project to a consortium of local operators. In Mongolia, the Company recently completed a Phase 1 geological program, defining structural trends with potential petroleum accumulations. A seismic program is currently underway. Details of these projects are located on the Company's website: www.manaspete.com
Undiscovered Equities is currently offering a complimentary trial subscription. To view the full report on Manas Petroleum visit: www.undiscoveredequities.com.
Undiscovered Equities is a leading provider of equity research on high impact oil and gas exploration projects. Our services include research analysis on the energy and precious metals markets, news and financial data, market commentary and the Undiscovered Equities newsletter. Undiscovered Equities' staff of small cap investment professionals is dedicated to providing the investment community with the tools and avenues necessary to capitalize on the energy boom invest their money wisely and build wealth. To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207Boca Raton, FL 33432
www.undiscoveredequities.com
disclaimer: www.undiscoveredequities.com/disclaimer.html
Drilling activity has reached currently a depth of 1970m and drilling is going ahead for additional 430m to the target depth of 2400m.
As the drilling program continues, the partners anticipate interesting intervals in subsequent hole sections, where primary objective reservoirs are interpreted to occur between 1680m and 2400m below ground level which is total well depth. The Prospect was generated as a result of the processing of seismic shot in a recent 2D seismic program by SPC. (South Petroleum Company)
The Huday Nazar replaces the previously planned drilling of the smaller and shallower East Chongora Prospect, which is also in the Soh License area. Acquisition of a total of 800 km of 2D seismic within the SPC licenses was completed as of late May, 2009 and seismic processing and interpretation is ongoing as part of a $ 54 million USD seismic, appraisal and drilling program undertaken by Santos International Pty. Ltd. Santos has the option to discontinue the program after drilling of the second well. Manas Petroleum has a 20% interest in the fully carried exploration program. Preparations by South Petroleum Company are underway for a deep drilling program expected to commence during the first half of 2010. Manas Petroleum's wholly-owned subsidiary, DWM Petroleum AG is the legal and beneficial owner of 25% of the issued share capital of South Petroleum Company, (SPC).
About Manas Petroleum:
Manas Petroleum is an international oil and gas company, focusing on activities in South-Eastern Europe, Central Asia and South America. In Albania, Manas has developed a large exploration project with a total resource potential (P50) of 3 billion barrels (Gustavson, 2008). Four blocks are now drill-ready. The council of ministers recently ratified the production-sharing contract on two bocks to DWM Petroleum, a subsidiary of Manas. A 51-101-compliant estimate is now being prepared. In Kyrgyzstan, Manas has signed a $ 54 million USD farm-out agreement with Santos LTD ADR, covering 1.2 billion barrels in place (Scott Pickford, 2005). Drilling is currently underway. Manas' Development of its license in Tajikistan is now covered by an option farm-in agreement with Santos LTD ADR, where a seismic program has been recently completed. In Chile, Manas and its U.S. partner, IPR, farmed out a large natural gas exploration project to a consortium of local operators. In Mongolia, the Company recently completed a Phase 1 geological program, defining structural trends with potential petroleum accumulations. A seismic program is currently underway. Details of these projects are located on the Company's website: www.manaspete.com
Undiscovered Equities is currently offering a complimentary trial subscription. To view the full report on Manas Petroleum visit: www.undiscoveredequities.com.
Undiscovered Equities is a leading provider of equity research on high impact oil and gas exploration projects. Our services include research analysis on the energy and precious metals markets, news and financial data, market commentary and the Undiscovered Equities newsletter. Undiscovered Equities' staff of small cap investment professionals is dedicated to providing the investment community with the tools and avenues necessary to capitalize on the energy boom invest their money wisely and build wealth. To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207Boca Raton, FL 33432
www.undiscoveredequities.com
disclaimer: www.undiscoveredequities.com/disclaimer.html
Subscribe to:
Posts (Atom)